CanVasc consensus recommendations for the use of avacopan in antineutrophil cytoplasm antibody-associated vasculitis: 2022 addendum.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Turgeon David, Bakowsky Volodko, Baldwin Corisande, Cabral David A, Clements-Baker Marie, Clifford Alison, Cohen Tervaert Jan Willem, Dehghan Natasha, Ennis Daniel, Famorca Leilani, Fifi-Mah Aurore, Girard Louis-Philippe, Lefebvre Frédéric, Liang Patrick, Makhzoum Jean-Paul, Massicotte-Azarniouch David, Mendel Arielle, Milman Nataliya, Reich Heather N, Robinson David B, Ross Carolyn, Rumsey Dax G, Soowamber Medha, Towheed Tanveer E, Trudeau Judith, Twilt Marinka, Yacyshyn Elaine, Yardimci Gozde K, Khalidi Nader, Barra Lillian, Pagnoux Christian
Аннотация
METHODS: An updated systematic literature review on avacopan (formerly, CCX168) using Medline, Embase, and the Cochrane Library was performed for publications up to September 2022. New recommendations were developed and categorized according to the EULAR grading levels, as done for previous CanVasc recommendations. A modified Delphi procedure and videoconferences were used to reach ≥80% consensus on the inclusion, wording and grading of each recommendation.
RESULTS: Three new recommendations were developed. They focus on avacopan therapy indication and duration, as well as timely glucocorticoid tapering.
CONCLUSION: These 2022 addended recommendations provide rheumatologists, nephrologists and other specialists caring for patients with AAV with guidance for the use of avacopan, based on current evidence and consensus from Canadian experts.